Aytu BioPharma, Inc. (AYTU) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $22.9M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAytu BioPharma, Inc. (AYTU) trades at $2.13 with MoonshotScore 27/100 (Grade F). Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally.
Price as of Sep 10, 2026 · Last analyzed: Sep 2, 2026Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc.
AYTU stock analysis for 2026: The stored analyst price target for Aytu BioPharma, Inc. is $9.33; its date is unknown, so no upside or downside is derived from it against the current price of $2.13. The AI MoonshotScore is 27/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
These figures come from statements filed 12 months ago — the most recent this company has published.
AYTU: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Strongest side: Valuation (8/10, Moderate). Weakest side: Financial Safety (2/10, Weak).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Aytu BioPharma, Inc. Company Overview
Who Are AYTU's Competitors?
AYTU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BGM BGM Group Ltd. | $0.28 | +0.92% | $105M | 455-pillar |
| GRUSF Grown Rogue International Inc. | $0.44 | -2.16% | $110M | 439-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are the Key Risks for AYTU?
Financial-distress signal — its Altman Z-Score of -4.52 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scored on 70% of our measures
- ● Price is current
- ● No filing on record
- ● Covered by analysts
Why 27?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.54 Enterprise value vs sales (Valuation)
- +0.54 Price to book (Valuation)
- +0.43 Gross profit per dollar of assets (Business Quality)
What is holding it back
- -0.73 Net margin (Business Quality)
- -0.54 Debt to equity (Financial Strength)
- -0.54 Earnings yield (Valuation)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -1.68 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 21 |
| 2026-08-26 | 21 |
| 2026-08-29 | 21 |
| 2026-09-01 | 22 |
| 2026-09-04 | 22 |
| 2026-09-07 | 22 |
| 2026-09-10 | 22 |
What changed?
The grade moved from 21 to 22 (+1).
What moved it up or down:
- +17 Valuation
- +3 Business Quality
- +3 Growth
Held back by:
- -9 Momentum
Over the same 18 days the stock moved -10.1%.
Insider Activity
Over the past six months, Aytu BioPharma, Inc. insiders filed 8 SEC Form 4 transactions — 0 sales and 8 purchases. On net that is roughly 130K shares acquired (about $0) — insiders putting money in tends to read as conviction.
AYTU Valuation & Market Position
With a $22.9M market cap, Aytu BioPharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, AYTU's quantitative score of 27/100 is below the peer average of 46/100.
Key Financial Metrics
Return on assets is -30.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 9.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -144.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Aytu BioPharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.52 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Aytu BioPharma, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1841.4% below estimates on average.
Forward Outlook
Wall Street analysts project Aytu BioPharma, Inc. revenue of about $53.7M for fiscal 2026, with EPS near $-1.06.
Quarterly Financial Performance: Aytu BioPharma, Inc.
Revenue for Aytu BioPharma, Inc. came in at $12.4M during Mar 2026, a 18.2% contraction versus the preceding quarter. The company recorded a net loss of $5.6M, with diluted EPS of $-0.53. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in its sector. Across the four most recent quarters, AYTU averaged $-1.10 in diluted EPS.
AYTU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Mar 2026 | $12M | -$6M | -$0.53 |
| Dec 2025 | $15M | -$11M | -$1.05 |
| Sep 2025 | $14M | $2M | $0.10 |
| Jun 2025 | $15M | -$20M | -$2.92 |
Based on FMP financials and quantitative analysis
AYTU Latest News
-
AWM Investment Company Inc. Invests $1.33 Million in Aytu BioPharma Inc. $AYTU
defenseworld.net · Aug 26, 2026
-
New Strong Sell Stocks for July 20th
Yahoo! Finance: AYTU News · Jul 20, 2026
-
New Strong Sell Stocks for July 20th
zacks.com · Jul 20, 2026
-
New Strong Sell Stocks for July 16th
Yahoo! Finance: AYTU News · Jul 16, 2026
AYTU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AYTU.
Price Targets
Consensus target: $9.33
AYTU MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. AYTU scores 27/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
AWM Investment Company Inc. Invests $1.33 Million in Aytu BioPharma Inc. $AYTU
New Strong Sell Stocks for July 20th
New Strong Sell Stocks for July 20th
New Strong Sell Stocks for July 16th
Latest Aytu BioPharma, Inc. Analysis
What Investors Ask About Aytu BioPharma, Inc. (AYTU)
What does the AI Score mean for AYTU?
AYTU holds an AI Score of 27/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is AYTU a good stock?
Stock Expert AI does not rate AYTU buy, sell or hold. Aytu BioPharma, Inc. carries a MoonshotScore of 27/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for AYTU?
Aytu BioPharma, Inc. (AYTU) holds an AI score of 27/100 (low). Not financial advice.
How frequently does AYTU data refresh on this page?
AYTU's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AYTU's recent stock price performance?
Aytu BioPharma, Inc. (AYTU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AYTU overvalued or undervalued right now?
Aytu BioPharma, Inc. (AYTU) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of AYTU?
Yes, most major brokerages offer fractional shares of Aytu BioPharma, Inc. (AYTU) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track AYTU's earnings and financial reports?
Aytu BioPharma, Inc. (AYTU) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for AYTU earnings announcements.
What should investors new to AYTU understand first?
Aytu BioPharma, Inc. (AYTU) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 27/100. With a market cap of $22.9M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.